Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Diaceutics ( (GB:DXRX) ) has shared an update.
Diaceutics has extended the lease on its Belfast headquarters with O’Connor & McCann Limited, a related party due to the involvement of Non-Executive Chair Peter Keeling, in a move that secures its Northern Ireland base through August 2036. The annual rent will rise from the current level to £235,000 from August 2026, with an open market rent review scheduled for August 2031, while all key terms, including the right to sub‑lease, remain intact.
The board, excluding Keeling, concluded after consulting the company’s nominated adviser that the lease extension is fair and reasonable for shareholders under AIM rules. By locking in its headquarters location without an early termination option, Diaceutics underpins operational continuity as it continues to deliver precision medicine commercialisation services to major pharmaceutical and biotech clients.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £215.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on DXRX Stock
According to Spark, TipRanks’ AI Analyst, DXRX is a Neutral.
Diaceutics’ strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock’s valuation is also concerning due to negative earnings.
To see Spark’s full report on DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a technology and solutions provider to the global pharma and biotech industry, focused on enabling the commercialisation of precision medicines. The company supports leading drugmakers with data analytics, scientific and advisory services delivered via its DXRX – The Diagnostics Network platform, aiming to ensure patients receive the right diagnostic tests and therapies.
Average Trading Volume: 116,331
Technical Sentiment Signal: Buy
Current Market Cap: £139.6M
For detailed information about DXRX stock, go to TipRanks’ Stock Analysis page.